Compare VCEL & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VCEL | BHVN |
|---|---|---|
| Founded | 1989 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | 2022 |
| Metric | VCEL | BHVN |
|---|---|---|
| Price | $36.30 | $10.80 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $57.75 | $29.08 |
| AVG Volume (30 Days) | 588.4K | ★ 2.4M |
| Earning Date | 05-07-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 60.00 | 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $276,259,000.00 | N/A |
| Revenue This Year | $19.40 | N/A |
| Revenue Next Year | $18.24 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $28.95 | $7.48 |
| 52 Week High | $45.97 | $18.57 |
| Indicator | VCEL | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 54.50 |
| Support Level | $35.85 | $8.25 |
| Resistance Level | $38.31 | $11.95 |
| Average True Range (ATR) | 1.57 | 0.89 |
| MACD | 0.16 | 0.16 |
| Stochastic Oscillator | 81.12 | 66.14 |
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.